Nakamura K - Search Results

1

A Potent Blood-Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model.

Machida Y, Nakagawa M, Matsunaga H, Yamaguchi M, Ogawara Y, Shima Y, Yamagata K, Katsumoto T, Hattori A, Itoh M, Seki T, Nishiya Y, Nakamura K, Suzuki K, Imaoka T, Baba D, Suzuki M, Sampetrean O, Saya H, Ichimura K, Kitabayashi I. Machida Y, et al. Among authors: nakamura k. Mol Cancer Ther. 2020 Feb;19(2):375-383. doi: 10.1158/1535-7163.MCT-18-1349. Epub 2019 Nov 14. Mol Cancer Ther. 2020. PMID: 31727689

2

Physiologically Based Pharmacokinetic Modeling for Quantitative Prediction of Exposure to a Human Disproportionate Metabolite of the Selective Na_V1.7 Inhibitor DS-1971a, a Mixed Substrate of Cytochrome P450 and Aldehyde Oxidase, Using Chimeric Mice With Humanized Liver.

Asano D, Nakamura K, Nishiya Y, Shiozawa H, Takakusa H, Shibayama T, Inoue SI, Shinozuka T, Hamada T, Yahara C, Watanabe N, Yoshinari K. Asano D, et al. Among authors: nakamura k. Drug Metab Dispos. 2023 Jan;51(1):67-80. doi: 10.1124/dmd.122.001000. Epub 2022 Oct 23. Drug Metab Dispos. 2023. PMID: 36273823

3

Effects of a combined treatment regimen consisting of Hsp90 inhibitor DS-2248 and radiation in vitro and in a tumor mouse model.

Kondo T, Shibamoto Y, Kawai T, Sugie C, Wang Z, Nakamura K, Murai T, Manabe Y, Nakashima M, Matsuo M. Kondo T, et al. Among authors: nakamura k. Transl Cancer Res. 2021 Jun;10(6):2767-2776. doi: 10.21037/tcr-21-71. Transl Cancer Res. 2021. PMID: 35116587 Free PMC article.

4

Integration of In Silico Pharmacokinetic Modeling Approaches Into In Vitro Dissolution Profiles to Predict Bioavailability of a Poorly Soluble Compound.

Kato T, Watanabe T, Nakamura K, Ando S. Kato T, et al. Among authors: nakamura k. J Pharm Sci. 2019 Nov;108(11):3723-3728. doi: 10.1016/j.xphs.2019.06.026. Epub 2019 Jul 3. J Pharm Sci. 2019. PMID: 31278915

5

UNC569-induced Morphological Changes in Pigment Epithelia and Photoreceptor Cells in the Retina through MerTK Inhibition in Mice.

Sayama A, Okado K, Nakamura K, Kawaguchi T, Iguchi T, Makino T, Yabe K, Kai K, Mori K. Sayama A, et al. Among authors: nakamura k. Toxicol Pathol. 2018 Feb;46(2):193-201. doi: 10.1177/0192623317749469. Epub 2018 Jan 8. Toxicol Pathol. 2018. PMID: 29310530

6

Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process.

Watanabe A, Nakamura K, Okudaira N, Okazaki O, Sudo K. Watanabe A, et al. Among authors: nakamura k. Drug Metab Dispos. 2007 Jul;35(7):1232-8. doi: 10.1124/dmd.107.015016. Epub 2007 Mar 28. Drug Metab Dispos. 2007. PMID: 17392390

7

A Controlled Release System for Long-Acting Intravitreal Delivery of Small Molecules.

Machinaga N, Ashley GW, Reid R, Yamasaki A, Tanaka K, Nakamura K, Yabe Y, Yoshigae Y, Santi DV. Machinaga N, et al. Among authors: nakamura k. Transl Vis Sci Technol. 2018 Aug 28;7(4):21. doi: 10.1167/tvst.7.4.21. eCollection 2018 Jul. Transl Vis Sci Technol. 2018. PMID: 30174998 Free PMC article.

8

Effect of ion suppression on judgment of enzyme inhibition and avoidance of error by utilizing a stable isotope-labeled probe substrate: example of CYP3A4 inhibition with [13C4,15N] labeled midazolam as a substrate.

Nakamura K, Watanabe A, Okudaira N, Okazaki O, Sudo K. Nakamura K, et al. Drug Metab Pharmacokinet. 2007 Apr;22(2):113-8. doi: 10.2133/dmpk.22.113. Drug Metab Pharmacokinet. 2007. PMID: 17495418 Free article.

9

Structure-activity relationships of 1,3-benzoxazole-4-carbonitriles as novel antifungal agents with potent in vivo efficacy.

Kuroyanagi J, Kanai K, Horiuchi T, Takeshita H, Kobayashi S, Achiwa I, Yoshida K, Nakamura K, Kawakami K. Kuroyanagi J, et al. Among authors: nakamura k. Chem Pharm Bull (Tokyo). 2011;59(3):341-52. doi: 10.1248/cpb.59.341. Chem Pharm Bull (Tokyo). 2011. PMID: 21372416 Free article.

10

Bioequivalence and rapid absorption of zolmitriptan nasal spray compared with oral tablets in healthy Japanese subjects.

Uemura N, Onishi T, Mitaniyama A, Kaneko T, Ninomiya K, Nakamura K, Tateno M. Uemura N, et al. Among authors: nakamura k. Clin Drug Investig. 2005;25(3):199-208. doi: 10.2165/00044011-200525030-00006. Clin Drug Investig. 2005. PMID: 17523769

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

14,514 results

Search Page